ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 590,58
-0,55%
Dow Jones
40 211,72
0,53%
DAX
18 505,18
-0,51%
Brent Oil
83,635
-0,84%
Bitcoin
62 839,08
-3,10%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
02/05/202222h01GlobeNewswire Inc.Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
02/05/202213h30GlobeNewswire Inc.Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering ConferenceNASDAQ:NTLAIntellia Therapeutics Inc
28/04/202213h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202205h25TipRanksJMP Securities Reiterates Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
10/03/202211h37TipRanksFDA Grants Orphan Drug Designation for Intellia’s NTLA-5001; Shares UpNASDAQ:NTLAIntellia Therapeutics Inc
09/03/202222h53Dow Jones NewsIntellia Therapeutics Gets FDA Orphan Drug Designation for Acute Myeloid Leukemia TreatmentNASDAQ:NTLAIntellia Therapeutics Inc
09/03/202222h01GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia NASDAQ:NTLAIntellia Therapeutics Inc
04/03/202223h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
04/03/202223h04Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
04/03/202212h35TipRanksIntellia Therapeutics (NTLA) Received its Third Buy in a RowNASDAQ:NTLAIntellia Therapeutics Inc
01/03/202213h30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid LeukemiaNASDAQ:NTLAIntellia Therapeutics Inc
28/02/202222h02PR Newswire (US)Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinNASDAQ:NTLAIntellia Therapeutics Inc
28/02/202222h01GlobeNewswire Inc.Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinNASDAQ:NTLAIntellia Therapeutics Inc
24/02/202223h31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
24/02/202222h28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
24/02/202213h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
23/02/202214h00GlobeNewswire Inc.Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based TherapiesNASDAQ:NTLAIntellia Therapeutics Inc
17/02/202213h30GlobeNewswire Inc.Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022NASDAQ:NTLAIntellia Therapeutics Inc
15/02/202213h30GlobeNewswire Inc.Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with CancerNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202212h29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
09/02/202215h21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NTLAIntellia Therapeutics Inc
03/02/202213h30GlobeNewswire Inc.Intellia Therapeutics Announces Acquisition of Rewrite TherapeuticsNASDAQ:NTLAIntellia Therapeutics Inc
14/01/202210h11TipRanksIntellia Therapeutics (NTLA) Gets a Buy Rating from Wells FargoNASDAQ:NTLAIntellia Therapeutics Inc
07/01/202206h25TipRanksAnalysts Conflicted on These Healthcare Names: Stryker (SYK) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
06/01/202213h30GlobeNewswire Inc.Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022NASDAQ:NTLAIntellia Therapeutics Inc
05/01/202222h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
05/01/202222h01GlobeNewswire Inc.Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022NASDAQ:NTLAIntellia Therapeutics Inc
05/01/202218h05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from H.C. WainwrightNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202213h30GlobeNewswire Inc.Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune DiseasesNASDAQ:NTLAIntellia Therapeutics Inc
29/12/202122h21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

NYSE
STZ.B
Constellation Brands
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés